These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15319673)

  • 1. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen.
    Cohen CJ; Clumeck N; Molina JM; Thompson M; Patel K; Wintfeld N; Green J
    J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1140-6. PubMed ID: 15319673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
    Nelson M; Arastéh K; Clotet B; Cooper DA; Henry K; Katlama C; Lalezari JP; Lazzarin A; Montaner JS; O'Hearn M; Piliero PJ; Reynes J; Trottier B; Walmsley SL; Cohen C; Eron JJ; Kuritzkes DR; Lange J; Stellbrink HJ; Delfraissy JF; Buss NE; Donatacci L; Wat C; Smiley L; Wilkinson M; Valentine A; Guimaraes D; Demasi R; Chung J; Salgo MP
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):404-12. PubMed ID: 16280694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
    Reynes J; Arastéh K; Clotet B; Cohen C; Cooper DA; Delfraissy JF; Eron JJ; Henry K; Katlama C; Kuritzkes DR; Lalezari JP; Lange J; Lazzarin A; Montaner JS; Nelson M; O' Hearn M; Stellbrink HJ; Trottier B; Walmsley SL; Buss NE; Demasi R; Chung J; Donatacci L; Guimaraes D; Rowell L; Valentine A; Wilkinson M; Salgo MP
    AIDS Patient Care STDS; 2007 Aug; 21(8):533-43. PubMed ID: 17711378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study.
    Bonora S; Calcagno A; Cometto C; Fontana S; Aguilar D; D'Avolio A; Gonzalez de Requena D; Maiello A; Dal Conte I; Lucchini A; Di Perri G
    Infection; 2012 Feb; 40(1):69-75. PubMed ID: 22135137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).
    Boulet T; Pavie J; Charreau I; Braun J; Reynes J; Morlat P; Piroth L; Spire B; Molina JM; Aboulker JP;
    HIV Clin Trials; 2010; 11(5):283-93. PubMed ID: 21126958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
    Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
    Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
    N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure.
    Cossarini F; Galli L; Sagnelli C; Gianotti N; Hasson H; Clementi M; Soria A; Salpietro S; Lazzarin A; Castagna A
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):179-84. PubMed ID: 19352200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of education and support on the tolerability and quality of life in a cohort of HIV-1 infected patients treated with enfuvirtide (SURCOUF Study).
    Allavena C; Prazuck T; Reliquet V; Verdon R; Perré P; Le Moal G; Billaud E; Raffi F
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(4):187-92. PubMed ID: 18599881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
    Trottier B; Walmsley S; Reynes J; Piliero P; O'Hearn M; Nelson M; Montaner J; Lazzarin A; Lalezari J; Katlama C; Henry K; Cooper D; Clotet B; Arastéh K; Delfraissy JF; Stellbrink HJ; Lange J; Kuritzkes D; Eron JJ; Cohen C; Kinchelow T; Bertasso A; Labriola-Tompkins E; Shikhman A; Atkins B; Bourdeau L; Natale C; Hughes F; Chung J; Guimaraes D; Drobnes C; Bader-Weder S; Demasi R; Smiley L; Salgo MP
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):413-21. PubMed ID: 16280695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
    Streinu-Cercel A; de Gorgolas M; Müller M; Portilla J; Rugina S; Böcher W; Staszewski S; Pulik P; Rowell L; Salgo M; Stoll M
    HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide.
    Beatty G; Hunt P; Smith A; Hoh R; Huang W; Martin J; Deeks SG
    Antivir Ther; 2006; 11(3):315-9. PubMed ID: 16759047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
    DeJesus E; Gottlieb MS; Gathe JC; Greenberg ML; Guittari CJ; Zolopa AR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4315-9. PubMed ID: 18809940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.
    Hardy H; Skolnik PR
    Pharmacotherapy; 2004 Feb; 24(2):198-211. PubMed ID: 14998221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to enfuvirtide and its impact on treatment efficacy.
    Rockstroh J; Dejesus E; Donatacci L; Wat C; Bertasso A; Labriola-Tompkins E; Shikhman A; Atkins B; Guimaraes D; Wilkinson M; Thommes J; Rowell L; Demasi R; Salgo M
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):141-8. PubMed ID: 18240965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.
    Sax PE; Losina E; Weinstein MC; Paltiel AD; Goldie SJ; Muccio TM; Kimmel AD; Zhang H; Freedberg KA; Walensky RP
    J Acquir Immune Defic Syndr; 2005 May; 39(1):69-77. PubMed ID: 15851916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).
    Gripshover BM; Ribaudo H; Santana J; Gerber JG; Campbell TB; Hogg E; Jarocki B; Hammer SM; Kuritzkes DR;
    Antivir Ther; 2006; 11(5):619-23. PubMed ID: 16964830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1].
    Raffi F
    Med Mal Infect; 2004 Sep; 34 Spec No 1():8-17. PubMed ID: 15742550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.